{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:07:57Z","timestamp":1792267677931,"version":"4.4.0"},"reference-count":99,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T00:00:00Z","timestamp":1677110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The objective of this narrative review is to summarize the efficacy and safety of available therapies for rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), including in patients with central nervous system (CNS) metastases. Background information is provided on RET rearrangements in NSCLC and the molecular testing options available as well as an overview of clinical guidelines for molecular testing, which recommend broad molecular testing, including for RET rearrangements. The efficacy and safety of potential treatments for RET fusion-positive NSCLC, including multikinase inhibitors, RET-selective inhibitors, pemetrexed-based therapy, and immunotherapies are reviewed from Phase I\/II and `real-world\u2019 studies, alongside an overview of primary and secondary resistance mechanisms. The RET-selective inhibitors, selpercatinib and pralsetinib, are preferred first-line therapy options for patients with RET fusion-positive metastatic NSCLC and are recommended as subsequent therapy if RET inhibitors have not been used in the first-line setting.<\/jats:p>","DOI":"10.1093\/oncolo\/oyac264","type":"journal-article","created":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T18:35:21Z","timestamp":1677177321000},"page":"402-413","source":"Crossref","is-referenced-by-count":44,"title":["<i>RET<\/i> Fusion-Positive Non-small Cell Lung Cancer: The Evolving Treatment Landscape"],"prefix":"10.1093","volume":"28","author":[{"given":"Silvia","family":"Novello","sequence":"first","affiliation":[{"name":"University of Turin, Department of Oncology, AOU San Luigi , Orbassano (Turin ), Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Califano","sequence":"additional","affiliation":[{"name":"The Christie NHS Foundation Trust and Division of Cancer Sciences, The University of Manchester , Manchester , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Reinmuth","sequence":"additional","affiliation":[{"name":"Thoracic Oncology Department, Asklepios Lung Clinic , Munich-Gauting , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Tamma","sequence":"additional","affiliation":[{"name":"Medical Oncology, Eli Lilly and Company , Indianapolis, IN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarun","family":"Puri","sequence":"additional","affiliation":[{"name":"Medical Oncology, Eli Lilly and Company , Indianapolis, IN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,2,23]]},"reference":[{"issue":"3","key":"2023050815264287000_CIT0001","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2023050815264287000_CIT0002","author":"Cancer.org.","year":"2020"},{"issue":"30","key":"2023050815264287000_CIT0003","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1200\/JCO.2017.74.6065","article-title":"Systemic therapy for stage IV non-small cell lung cancer: American Society of Clinical Oncology clinical practice guideline update","volume":"35","author":"Hanna","year":"2017","journal-title":"J Clin Oncol"},{"issue":"9","key":"2023050815264287000_CIT0004","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1200\/JCO.20.03570","article-title":"Therapy for stage IV non-small cell lung cancer with driver alterations: ASCO and OH (CCO) joint guideline update","volume":"39","author":"Hanna","year":"2021","journal-title":"J Clin Oncol"},{"key":"2023050815264287000_CIT0005","author":"European Society for Medical Oncology."},{"issue":"3","key":"2023050815264287000_CIT0006","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/nm.2673","article-title":"Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies","volume":"18","author":"Lipson","year":"2012","journal-title":"Nat Med"},{"issue":"8","key":"2023050815264287000_CIT0007","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1158\/1078-0432.CCR-16-1679","article-title":"RET aberrations in diverse cancers: next-generation sequencing of 4,871 patients","volume":"23","author":"Kato","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2023050815264287000_CIT0008","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nrc3680","article-title":"RET revisited: expanding the oncogenic portfolio","volume":"14","author":"Mulligan","year":"2014","journal-title":"Nat Rev Cancer"},{"issue":"35","key":"2023050815264287000_CIT0009","doi-asserted-by":"crossref","first-page":"4352","DOI":"10.1200\/JCO.2012.44.1477","article-title":"RET fusions define a unique molecular and clinicopathologic subtype of non-small cell lung cancer","volume":"30","author":"Wang","year":"2012","journal-title":"J Clin Oncol"},{"issue":"6","key":"2023050815264287000_CIT0010","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1038\/bjc.2014.36","article-title":"RET-rearranged non-small cell lung carcinoma: a clinicopathological and molecular analysis","volume":"110","author":"Tsuta","year":"2014","journal-title":"Br J Cancer"},{"issue":"10299","key":"2023050815264287000_CIT0011","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","article-title":"Lung cancer","volume":"398","author":"Thai","year":"2021","journal-title":"Lancet"},{"key":"2023050815264287000_CIT0012","article-title":"Identifying novel oncogenic RET mutations and characterising their sensitivity to RET-specific inhibitors","author":"Zhao","year":"2020","journal-title":"J Med Genet"},{"key":"2023050815264287000_CIT0013","doi-asserted-by":"crossref","first-page":"1758835920928634","DOI":"10.1177\/1758835920928634","article-title":"Current management of RET rearranged non-small cell lung cancer","volume":"12","author":"Stinchcombe","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"2023050815264287000_CIT0014","doi-asserted-by":"crossref","first-page":"932353","DOI":"10.3389\/fonc.2022.932353","article-title":"RET signaling pathway and RET inhibitors in human cancer","volume":"12","author":"Regua","year":"2022","journal-title":"Front Oncol"},{"key":"2023050815264287000_CIT0015","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3389\/fphys.2019.00216","article-title":"Discovery stories of RET fusions in lung cancer: a mini-review","volume":"10","author":"Takeuchi","year":"2019","journal-title":"Front Physiol"},{"issue":"10","key":"2023050815264287000_CIT0016","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/j.jtho.2018.07.004","article-title":"Frequency of brain metastases and multikinase inhibitor outcomes in patients with RET-rearranged lung cancers","volume":"13","author":"Drilon","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"3","key":"2023050815264287000_CIT0017","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1101\/gr.133645.111","article-title":"A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing","volume":"22","author":"Ju","year":"2012","journal-title":"Genome Res"},{"issue":"3","key":"2023050815264287000_CIT0018","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/nrclinonc.2017.175","article-title":"Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes","volume":"15","author":"Drilon","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"2023050815264287000_CIT0019","doi-asserted-by":"crossref","first-page":"e349","DOI":"10.1016\/j.cllc.2020.02.006","article-title":"Association between RET fusions and efficacy of pemetrexed-based chemotherapy for patients with advanced NSCLC in China: a multicenter retrospective study","volume":"21","author":"Shen","year":"2020","journal-title":"Clin Lung Cancer"},{"issue":"1","key":"2023050815264287000_CIT0020","doi-asserted-by":"crossref","first-page":"314","DOI":"10.21037\/tlcr-20-549","article-title":"Phase 1\/2 study of alectinib in RET-rearranged previously-treated non-small cell lung cancer (ALL-RET)","volume":"10","author":"Takeuchi","year":"2021","journal-title":"Transl Lung Cancer Res"},{"issue":"12","key":"2023050815264287000_CIT0021","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1016\/j.jtho.2020.08.011","article-title":"Molecular characterization and clinical outcomes in RET-rearranged NSCLC","volume":"15","author":"Tan","year":"2020","journal-title":"J Thorac Oncol"},{"issue":"suppl 7","key":"2023050815264287000_CIT0022","first-page":"S1001S448","article-title":"Relationship between RET fusion partner and treatment outcomes in patients (pts) with non-small cell lung cancer (NSCLC) from the phase I\/II ARROW study and real-world data (RWD) [abstract no. 984P]","volume":"33","author":"Gadgeel","year":"2022","journal-title":"Ann Oncol"},{"issue":"1","key":"2023050815264287000_CIT0023","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jtho.2017.10.021","article-title":"Clinical and translational implications of RET rearrangements in non-small cell lung cancer","volume":"13","author":"Ferrara","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"3","key":"2023050815264287000_CIT0024","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.annonc.2020.11.021","article-title":"ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research","volume":"32","author":"Belli","year":"2021","journal-title":"Ann Oncol"},{"issue":"10","key":"2023050815264287000_CIT0025","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1016\/j.drudis.2018.05.015","article-title":"Next-generation sequencing in drug development: Target identification and genetically stratified clinical trials","volume":"23","author":"Doostparast Torshizi","year":"2018","journal-title":"Drug Discov Today"},{"issue":"6","key":"2023050815264287000_CIT0026","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.jtho.2020.01.019","article-title":"Optimizing mutation and fusion detection in NSCLC by sequential DNA and RNA sequencing","volume":"15","author":"Cohen","year":"2020","journal-title":"J Thorac Oncol"},{"key":"2023050815264287000_CIT0027","doi-asserted-by":"crossref","article-title":"RET fusion testing in advanced non-small cell lung carcinoma patients: the RETING study","author":"Conde","DOI":"10.1016\/j.jtho.2021.08.183"},{"issue":"Aug","key":"2023050815264287000_CIT0028","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.lungcan.2019.06.004","article-title":"Sensitivity of next-generation sequencing assays detecting oncogenic fusions in plasma cell-free DNA","volume":"134","author":"Supplee","year":"2019","journal-title":"Lung Cancer"},{"issue":"2","key":"2023050815264287000_CIT0029","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2018.4305","article-title":"Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non-small cell lung cancer","volume":"5","author":"Aggarwal","year":"2019","journal-title":"JAMA Oncol"},{"key":"2023050815264287000_CIT0030","author":"National Comprehensive Cancer Network."},{"issue":"4","key":"2023050815264287000_CIT0031","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jmoldx.2018.04.002","article-title":"Validity of targeted next-generation sequencing in routine care for identifying clinically relevant molecular profiles in non-small cell lung cancer: results of a 2-year experience on 1343 samples","volume":"20","author":"Legras","year":"2018","journal-title":"J Mol Diagn"},{"key":"2023050815264287000_CIT0032","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.lungcan.2021.02.026","article-title":"The evolving landscape of biomarker testing for non-small cell lung cancer in Europe","volume":"154","author":"Kerr","year":"2021","journal-title":"Lung Cancer"},{"issue":"Feb","key":"2023050815264287000_CIT0033","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.lungcan.2020.10.012","article-title":"Biomarker testing in non-small cell lung cancer in routine care: analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP registry (AIO-TRK-0315)","volume":"152","author":"Griesinger","year":"2021","journal-title":"Lung Cancer"},{"issue":"24","key":"2023050815264287000_CIT0034","first-page":"7284","article-title":"ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases","volume":"62","author":"Carlomagno","year":"2002","journal-title":"Cancer Res"},{"issue":"3","key":"2023050815264287000_CIT0035","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nm.2644","article-title":"KIF5B-RET fusions in lung adenocarcinoma","volume":"18","author":"Kohno","year":"2012","journal-title":"Nat Med"},{"issue":"12","key":"2023050815264287000_CIT0036","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1097\/JTO.0b013e3182721ed1","article-title":"Identification of CCDC6-RET fusion in the human lung adenocarcinoma cell line, LC-2\/ad","volume":"7","author":"Matsubara","year":"2012","journal-title":"J Thorac Oncol"},{"issue":"7","key":"2023050815264287000_CIT0037","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1470-2045(10)70132-7","article-title":"Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial","volume":"11","author":"Herbst","year":"2010","journal-title":"Lancet Oncol"},{"issue":"8","key":"2023050815264287000_CIT0038","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1200\/JCO.2010.28.5981","article-title":"Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer","volume":"29","author":"Natale","year":"2011","journal-title":"J Clin Oncol"},{"issue":"10","key":"2023050815264287000_CIT0039","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1200\/JCO.2011.36.1709","article-title":"Vandetanib versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR)","volume":"30","author":"Lee","year":"2012","journal-title":"J Clin Oncol"},{"issue":"8","key":"2023050815264287000_CIT0040","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1200\/JCO.2010.29.5717","article-title":"Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial","volume":"29","author":"De Boer","year":"2011","journal-title":"J Clin Oncol"},{"issue":"16","key":"2023050815264287000_CIT0041","first-page":"4645","article-title":"ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration","volume":"62","author":"Wedge","year":"2002","journal-title":"Cancer Res"},{"issue":"May","key":"2023050815264287000_CIT0042","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.lungcan.2021.03.002","article-title":"Final survival results for the phase II study of vandetanib in previously treated patients with RET-rearranged advanced non-small cell lung cancer","volume":"155","author":"Yoh","year":"2021","journal-title":"Lung Cancer"},{"issue":"2","key":"2023050815264287000_CIT0043","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/annonc\/mdw559","article-title":"Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial","volume":"28","author":"Lee","year":"2017","journal-title":"Ann Oncol"},{"issue":"15 suppl","key":"2023050815264287000_CIT0044","doi-asserted-by":"crossref","first-page":"9035","DOI":"10.1200\/JCO.2018.36.15_suppl.9035","article-title":"Multi-kinase RET inhibitor vandetanib combined with mTOR inhibitor everolimus in patients with RET rearranged non-small cell lung cancer","volume":"36","author":"Subbiah","year":"2018","journal-title":"J Clin Oncol"},{"issue":"12","key":"2023050815264287000_CIT0045","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","article-title":"Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth","volume":"10","author":"Yakes","year":"2011","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"2023050815264287000_CIT0046","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S1470-2045(16)30562-9","article-title":"Cabozantinib in patients with advanced RET-rearranged non-small cell lung cancer: an open-label, single-centre, phase 2, single-arm trial","volume":"17","author":"Drilon","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1 Suppl 1","key":"2023050815264287000_CIT0047","doi-asserted-by":"crossref","first-page":"S286","DOI":"10.1016\/j.jtho.2016.11.291","article-title":"A phase 2 study of cabozantinib for patients with advanced RET-rearranged lung cancers","volume":"12","author":"Drilon","year":"2017","journal-title":"J Thorac Oncol"},{"issue":"13","key":"2023050815264287000_CIT0048","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1200\/JCO.2016.70.9352","article-title":"Targeting RET in patients with RET-rearranged lung cancers: results from the global, multicenter RET registry","volume":"35","author":"Gautschi","year":"2017","journal-title":"J Clin Oncol"},{"issue":"10","key":"2023050815264287000_CIT0049","doi-asserted-by":"crossref","first-page":"6455","DOI":"10.21037\/tcr-20-754","article-title":"The clinical significance of RET gene fusion among Chinese patients with lung cancer","volume":"9","author":"Xing","year":"2020","journal-title":"Transl Cancer Res"},{"issue":"3","key":"2023050815264287000_CIT0050","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ijc.23131","article-title":"E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition","volume":"122","author":"Matsui","year":"2008","journal-title":"Int J Cancer"},{"issue":"1","key":"2023050815264287000_CIT0051","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.canlet.2013.07.007","article-title":"Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models","volume":"340","author":"Okamoto","year":"2013","journal-title":"Cancer Lett"},{"key":"2023050815264287000_CIT0052","doi-asserted-by":"crossref","first-page":"638747","DOI":"10.1155\/2014\/638747","article-title":"Antitumor activity of lenvatinib (E7080): An angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models","volume":"2014","author":"Tohyama","year":"2014","journal-title":"J Thyroid Res"},{"issue":"17","key":"2023050815264287000_CIT0053","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.1158\/1078-0432.CCR-07-5270","article-title":"Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase","volume":"14","author":"Matsui","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"Dec","key":"2023050815264287000_CIT0054","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.lungcan.2019.09.011","article-title":"A phase 2 study of lenvatinib in patients with RET fusion-positive lung adenocarcinoma","volume":"138","author":"Hida","year":"2019","journal-title":"Lung Cancer"},{"issue":"3","key":"2023050815264287000_CIT0055","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1158\/2159-8290.CD-18-0839","article-title":"A phase I\/Ib trial of the VEGFR-sparing multikinase RET inhibitor RXDX-105","volume":"9","author":"Drilon","year":"2019","journal-title":"Cancer Discov"},{"key":"2023050815264287000_CIT0056","author":"Selpercatinib (Retevmo)."},{"key":"2023050815264287000_CIT0057","author":"Union Register of medicinal products \u2013 Public health \u2013 European Commission."},{"issue":"9","key":"2023050815264287000_CIT0058","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2005653","article-title":"Efficacy of selpercatinib in RET fusion-positive non-small cell lung cancer","volume":"383","author":"Drilon","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"2023050815264287000_CIT0059","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1200\/JCO.22.00393","article-title":"Selpercatinib in patients with RET fusion-positive non-small cell lung cancer: updated safety and efficacy from the registrational LIBRETTO-001 phase I\/II trial","volume":"41","author":"Drilon","year":"2023","journal-title":"J Clin Oncol"},{"key":"2023050815264287000_CIT0060","author":"Pralsetinib (Gavreto)."},{"key":"2023050815264287000_CIT0061","author":"Pralsetinib (Gavreto)."},{"issue":"7","key":"2023050815264287000_CIT0062","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S1470-2045(21)00247-3","article-title":"Pralsetinib for RET fusion-positive non-small cell lung cancer (ARROW): a multi-cohort, open-label, phase 1\/2 study","volume":"22","author":"Gainor","year":"2021","journal-title":"Lancet Oncol"},{"issue":"11","key":"2023050815264287000_CIT0063","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.annonc.2022.08.002","article-title":"Safety and efficacy of pralsetinib in RET fusion\u2013positive non-small cell lung cancer including as first-line therapy: update from the ARROW trial","volume":"33","author":"Griesinger","year":"2022","journal-title":"Ann Oncol"},{"issue":"15 suppl","key":"2023050815264287000_CIT0064","doi-asserted-by":"crossref","first-page":"9089","DOI":"10.1200\/JCO.2021.39.15_suppl.9089","article-title":"Safety and efficacy of pralsetinib in patients with advanced RET fusion-positive non-small cell lung cancer: Update from the ARROW trial","volume":"39","author":"Curigliano","year":"2021","journal-title":"J Clin Oncol"},{"issue":"suppl 7","key":"2023050815264287000_CIT0065","first-page":"S1083S448","article-title":"Updated efficacy and safety data from the phase I\/II ARROW study of pralsetinib in patients (pts) with advanced RET fusion+ non-small cell lung cancer (NSCLC)","volume":"33","author":"Besse","year":"2022","journal-title":"Ann Oncol"},{"issue":"15 suppl","key":"2023050815264287000_CIT0066","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1200\/JCO.2021.39.15_suppl.3008","article-title":"BOS172738, a highly potent and selective RET inhibitor, for the treatment of RET-altered tumors including RET-fusion+ NSCLC and RET-mutant MTC: Phase 1 study results","volume":"39","author":"Schoffski","year":"2021","journal-title":"J Clin Oncol"},{"issue":"7","key":"2023050815264287000_CIT0067","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1093\/annonc\/mdw163","article-title":"Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers","volume":"27","author":"Drilon","year":"2016","journal-title":"Ann Oncol"},{"issue":"5","key":"2023050815264287000_CIT0068","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1093\/jjco\/hyaa019","article-title":"Characteristics and outcomes of RET-rearranged Korean non-small cell lung cancer patients in real-world practice","volume":"50","author":"Lee","year":"2020","journal-title":"Jpn J Clin Oncol"},{"issue":"Nov","key":"2023050815264287000_CIT0069","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.lungcan.2016.09.002","article-title":"Clinicopathologic characteristics, genetic variability and therapeutic options of RET rearrangements patients in lung adenocarcinoma","volume":"101","author":"Song","year":"2016","journal-title":"Lung Cancer"},{"issue":"15 suppl 1","key":"2023050815264287000_CIT0070","doi-asserted-by":"crossref","first-page":"8007","DOI":"10.1200\/jco.2015.33.15_suppl.8007","article-title":"Phase II study of cabozantinib for patients with advanced RET-rearranged lung cancers","volume":"33","author":"Drilon","year":"2015","journal-title":"J Clin Oncol"},{"issue":"7","key":"2023050815264287000_CIT0071","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s11864-019-0652-3","article-title":"When to consider immune checkpoint inhibitors in oncogene-driven non-small cell lung cancer?","volume":"20","author":"Mhanna","year":"2019","journal-title":"Curr Treat Options Oncol"},{"issue":"8","key":"2023050815264287000_CIT0072","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/annonc\/mdz167","article-title":"Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry","volume":"30","author":"Mazieres","year":"2019","journal-title":"Ann Oncol"},{"key":"2023050815264287000_CIT0073","article-title":"Immunophenotype and response to immunotherapy of RET-rearranged lung cancers","volume":"3","author":"Offin","year":"2019","journal-title":"JCO Precis Oncol"},{"issue":"11","key":"2023050815264287000_CIT0074","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1158\/2326-6066.CIR-16-0177","article-title":"Kinase regulation of human MHC class I molecule expression on cancer cells","volume":"4","author":"Brea","year":"2016","journal-title":"Cancer Immunol Res"},{"issue":"18","key":"2023050815264287000_CIT0075","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1158\/1078-0432.CCR-15-3101","article-title":"EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis","volume":"22","author":"Gainor","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2023050815264287000_CIT0076","doi-asserted-by":"crossref","first-page":"e000799","DOI":"10.1136\/esmoopen-2020-000799","article-title":"Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies","volume":"5","author":"Hegde","year":"2020","journal-title":"ESMO Open"},{"key":"2023050815264287000_CIT0077","author":"Marra","year":"2019"},{"issue":"11","key":"2023050815264287000_CIT0078","doi-asserted-by":"crossref","first-page":"893","DOI":"10.2217\/imt-2021-0035","article-title":"Efficacy of immune checkpoint inhibitor therapy in patients with RET fusion-positive non-small cell lung cancer","volume":"13","author":"Bhandari","year":"2021","journal-title":"Immunotherapy"},{"issue":"10","key":"2023050815264287000_CIT0079","doi-asserted-by":"crossref","first-page":"S851","DOI":"10.1016\/j.jtho.2019.08.1839","article-title":"P2.14-54 high incidence of CNS metastases in advanced or recurrent non-small cell lung cancer patients with RET fusion","volume":"14","author":"Lee","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"8","key":"2023050815264287000_CIT0080","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1093\/annonc\/mdy137","article-title":"Selective RET kinase inhibition for patients with RET-altered cancers","volume":"29","author":"Subbiah","year":"2018","journal-title":"Ann Oncol"},{"issue":"7","key":"2023050815264287000_CIT0081","doi-asserted-by":"crossref","first-page":"763","DOI":"10.2217\/fon-2020-0935","article-title":"Phase III study of selpercatinib versus chemotherapy \u00b1 pembrolizumab in untreated RET positive non-small cell lung cancer","volume":"17","author":"Solomon","year":"2021","journal-title":"Future Oncol"},{"issue":"1 suppl","key":"2023050815264287000_CIT0082","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1016\/j.jtho.2020.10.087","article-title":"AcceleRET lung: a phase 3 study of first-line pralsetinib in patients with RET-fusion+ advanced\/metastatic NSCLC [abstract no. PUL01.02]","volume":"16","author":"Besse","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"June 11","key":"2023050815264287000_CIT0083","first-page":"17588359211019617588359211019675","article-title":"Selpercatinib in RET fusion-positive non-small cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program","volume":"13","author":"Illini","year":"2021","journal-title":"Ther Adv Med Oncol"},{"issue":"suppl 7","key":"2023050815264287000_CIT0084","first-page":"S1065S448","article-title":"Pralsetinib in RET fusion-positive non-small cell lung cancer: a real-world data (RWD) analysis from the Italian expanded access program (EAP)","volume":"33","author":"Passaro","year":"2022","journal-title":"Ann Oncol"},{"key":"2023050815264287000_CIT0085","doi-asserted-by":"crossref","first-page":"102153","DOI":"10.1016\/j.ctrv.2021.102153","article-title":"Diagnostics, therapeutics and RET inhibitor resistance for RET fusion-positive non-small cell lung cancers and future perspectives","volume":"96","author":"Lu","year":"2021","journal-title":"Cancer Treat Rev"},{"issue":"12","key":"2023050815264287000_CIT0086","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.trecan.2021.07.003","article-title":"Precision therapy for RET-altered cancers with RET inhibitors","volume":"7","author":"Thein","year":"2021","journal-title":"Trends Cancer"},{"issue":"1","key":"2023050815264287000_CIT0087","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1038\/s41467-022-28848-x","article-title":"The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers","volume":"13","author":"Rosen","year":"2022","journal-title":"Nat Commun"},{"issue":"1","key":"2023050815264287000_CIT0088","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1158\/1078-0432.CCR-20-2278","article-title":"Overcoming MET-dependent resistance to selective RET inhibition in patients with RET fusion-positive lung cancer by combining selpercatinib with crizotinib","volume":"27","author":"Rosen","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2023050815264287000_CIT0089","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/j.annonc.2020.09.015","article-title":"Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small cell lung cancer","volume":"31","author":"Lin","year":"2020","journal-title":"Ann Oncol"},{"issue":"suppl 7","key":"2023050815264287000_CIT0090","first-page":"S1013S448","article-title":"Mechanism of primary and secondary resistance to RET inhibitors in patients with RET-positive advanced NSCLC [abstract no. 1007P]","volume":"33","author":"Marinello","year":"2022","journal-title":"Ann Oncol"},{"issue":"2","key":"2023050815264287000_CIT0091","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.annonc.2020.10.599","article-title":"Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations","volume":"32","author":"Subbiah","year":"2021","journal-title":"Ann Oncol"},{"issue":"4","key":"2023050815264287000_CIT0092","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jtho.2020.01.006","article-title":"RET solvent front mutations mediate acquired resistance to selective RET inhibition in RET-driven malignancies","volume":"15","author":"Solomon","year":"2020","journal-title":"J Thorac Oncol"},{"key":"2023050815264287000_CIT0093","author":"Gainor"},{"issue":"15 Suppl","key":"2023050815264287000_CIT0094","doi-asserted-by":"crossref","first-page":"e20626","DOI":"10.1200\/JCO.2019.37.15_suppl.e20626","article-title":"Clinical outcomes of NSCLC patients with acquired RET rearrangement after resistance to osimertinib","volume":"37","author":"Lu","year":"2019","journal-title":"J Clin Oncol"},{"issue":"3","key":"2023050815264287000_CIT0095","doi-asserted-by":"crossref","first-page":"S230","DOI":"10.1016\/j.jtho.2021.01.150","article-title":"Combination osimertinib plus selpercatinib for EGFR-mutant non-small cell lung cancer (NSCLC) with acquired RET fusions","volume":"16","author":"Rotow","year":"2021","journal-title":"J Thorac Oncol"},{"key":"2023050815264287000_CIT0096","author":"Miyazaki"},{"issue":"15 suppl","key":"2023050815264287000_CIT0097","doi-asserted-by":"crossref","first-page":"TPS9633","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS9633","article-title":"AcceleRET lung: a phase III study of first-line pralsetinib in patients (pts) with RET-fusion+ advanced\/metastatic non-small cell lung cancer (NSCLC)","volume":"38","author":"Besse","year":"2020","journal-title":"J Clin Oncol"},{"issue":"10","key":"2023050815264287000_CIT0098","doi-asserted-by":"crossref","first-page":"S975","DOI":"10.1016\/j.jtho.2021.08.262","article-title":"LIBRETTO-432: a placebo-controlled phase 3 study of adjuvant selpercatinib in stage IB-IIIA RET fusion-positive NSCLC [abstract no. P01.01]","volume":"16","author":"Goldman","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"9","key":"2023050815264287000_CIT0099","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.jtho.2020.05.002","article-title":"The International Association for the Study of Lung Cancer Global Survey on Molecular Testing in Lung Cancer","volume":"15","author":"Smeltzer","year":"2020","journal-title":"J Thorac Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/5\/402\/50247672\/oyac264.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/5\/402\/50247672\/oyac264.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T17:21:40Z","timestamp":1683566500000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/28\/5\/402\/7055843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,23]]},"references-count":99,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,2,23]]},"published-print":{"date-parts":[[2023,5,8]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyac264","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,5,1]]},"published":{"date-parts":[[2023,2,23]]}}}